share_log

EF Hutton Assumes Pasithea Therapeutics at Buy, Announces Price Target of $2

EF Hutton Assumes Pasithea Therapeutics at Buy, Announces Price Target of $2

EF Hutton 假设 Pasithea Therapeutics 处于买入状态,宣布目标股价为2美元
Benzinga ·  2023/06/01 01:49

EF Hutton analyst Elemer Piros assumes Pasithea Therapeutics (NASDAQ:KTTA) with a Buy rating and announces Price Target of $2.

EF Hutton分析师Elemer Piros假设Pasithea治疗公司(纳斯达克:KTTA)的评级为买入,并宣布目标价为2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发